HIV Drug Sales Rescue GSK's Second Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
"Stand-out" sales of Tivicay and Triumeq validate GSK's decision earlier this year to hang on to its stake in ViiV Healthcare.
You may also be interested in...
ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value
The British health care company has decided not to spin out a minority stake in its fast-growing HIV joint venture, in part because of feedback from investors against the idea.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.